Sentinel lymph node biopsy is accurate and prognostic in head and neck melanoma by Erman, Audrey B. et al.
Sentinel Lymph Node Biopsy Is Accurate and
Prognostic in Head and Neck Melanoma
Audrey B. Erman, MD1*; Ryan M. Collar, MD1*; Kent A. Griffith, MPH, MS2; Lori Lowe, MD3; Michael S. Sabel, MD4;
Christopher K. Bichakjian, MD5; Sandra L. Wong, MD4; Scott A. McLean, MD, PhD1; Riley S. Rees, MD6;
Timothy M. Johnson, MD5; and Carol R. Bradford, MD1
BACKGROUND: Sentinel lymph node biopsy (SLNB) has emerged as a widely used staging procedure for cutaneous
melanoma. However, debate remains around the accuracy and prognostic implications of SLNB for cutaneous mela-
noma arising in the head and neck, as previous reports have demonstrated inferior results to those in nonhead and
neck regions. Through the largest single-institution series of head and neck melanoma patients, the authors set out
to demonstrate that SLNB accuracy and prognostic value in the head and neck region are comparable to other sites.
METHODS: A prospectively collected database was queried for cutaneous head and neck melanoma patients who
underwent SLNB at the University of Michigan between 1997 and 2007. Primary endpoints included SLNB result, time
to recurrence, site of recurrence, and date and cause of death. Multivariate models were constructed for analyses.
RESULTS: Three hundred fifty-three patients were identified. A sentinel lymph node was identified in 352 of 353
patients (99.7%). Sixty-nine of the 353 (19.6%) patients had a positive SLNB. Seventeen of 68 patients (25%) under-
going completion lymphadenectomy after a positive SLNB result had at least 1 additional positive nonsentinel lymph
node. Patients with local control and a negative SLNB failed regionally in 4.2% of cases. Multivariate analysis revealed
positive SLNB status to be the most prognostic clinicopathologic predictor of poor outcome; hazard ratio was 4.23
for SLNB status and recurrence-free survival (P < .0001) and 3.33 for overall survival (P < .0001). CONCLUSIONS:
SLNB is accurate and its results are of prognostic importance for head and neck melanoma patients. Cancer
2012;118:1040-7. VC 2011 American Cancer Society.
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INTRODUCTION
First described byMorton et al in 1992, sentinel lymph node biopsy (SLNB) has become a common staging procedure for
cutaneous melanoma.1,2 Accurately predicting the status of the regional lymph node basin, a positive SLNB identifies a subset
of patients whomay benefit from completion lymphadenectomy and are candidates for adjuvant therapy and/or clinical trials.
Proximity of cranial nerves and ambiguous lymphatic drainage pose unique challenges to performing the SLNB pro-
cedure in the head and neck region.3-5 Two large series (n ¼ 3897) have demonstrated higher recurrence rates in previ-
ously mapped negative nodal basins in the head and neck region relative to other anatomic regions, suggesting inferior
SLNB accuracy.6,7 Furthermore, consistent correlation between SLNB status and overall survival (OS) is lacking in head
and neck melanoma series.8-10 Hence, despite the general adoption of SLNB for extremity and truncal cutaneous mela-
noma, there remains debate around SLNB accuracy and prognostic value in the head and neck region.
Through the largest single-institution series of head and neck melanoma patients, we set out to demonstrate that
SLNB accuracy and prognostic value in the head and neck region are comparable to other sites.
MATERIALS AND METHODS
Patients
This study was approved by the University of Michigan Institutional Review Board. A prospectively collected melanoma
database was queried for cutaneous head and neck melanoma patients who underwent SLNB at the University of
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Michigan between 1997 and 2007. All patients were ini-
tially evaluated at the University of Michigan Multidisci-
plinary Melanoma Clinic. All primary melanomas and
sentinel lymph node (SLN) histology slides were reviewed
by a dermatopathologist(s) in the melanoma program,
with a standard 14-point melanoma profile generated for
the primary lesion. Patients with melanoma >1.0 mm
Breslow depth or between 0.75 and 0.99 mm Breslow
depth with other adverse pathologic or clinical findings
were counseled for consideration of SLNB as previously
described.11 Patients with a positive SLNB received rec-
ommendation for completion lymphadenectomy fol-
lowed by referral to medical oncology for consideration of
adjuvant therapy, including high-dose interferon alfa-2b
or clinical trials. Patients with a negative SLNB were fol-
lowed clinically for recurrence.
SLNB
Patients underwent preoperative lymphoscintigraphy
using techniques previously described 2 to 4 hours before
surgery.12,13 All SLNB procedures were performed by sur-
geons specializing exclusively in the head and neck region
(C.R.B. and R.S.R.). After resection of the primary mela-
noma site with margins dictated by the National Compre-
hensive Cancer Network guidelines, nodal basin
radioactivity was measured with handheld gamma probes
(Navigator GPS; RMD Instruments, Waterton, Mass).14
One- to 3-cm incisions were made directly over sites of
highest radioactivity and parallel to relaxed skin tension
lines. In the majority of cases, facial nerve monitoring or
handheld nerve monitors were used to minimize neural
injury risk during dissection. In addition to radioactivity
level, 1 author (C.R.B.) also routinely used intradermal
blue dye (isosulfan or methylene blue) to locate the SLN.
Another author (R.S.R.) used intradermal blue dye in
cases where shine through limited lymph node identifica-
tion, particularly in the parotid basin. Shine through
occurs when gamma emission from the injected primary
site artificially elevates the measured radioactivity of
nearby nodal basins, rendering those gamma counts inac-
curate. Lymph node removal continued until the opera-
tive bed emitted<10% of the ex vivo count of the highest
emitting lymph node and until any blue dyed or suspi-
cious appearing nodes were removed. All lymph nodes
were serially sectioned and evaluated histologically with
hematoxylin and eosin stained sections and immunostains
(S-100, Melan-A, and/or HMB-45) as previously
described.15
Statistical Analysis
Primary endpoints included SLNB result, time to recur-
rence, site of recurrence, and date and cause of death. Sec-
ondary endpoints included failure to identify a SLN at
surgery and cranial nerve injuries. A false-negative SLNB
was defined as a negative SLNB in a patient who devel-
oped regional recurrence during follow-up without previ-
ously or simultaneously diagnosed local or in-transit
recurrence. Data was collected by database query, chart
review, telephone interviews, and the Social Security
Death Index.
All time to event endpoints were calculated from the
date of SLNB. OS was calculated from SLNB date until
death or last follow-up. Recurrence-free survival (RFS)
was calculated from SLNB date until recurrence, death, or
last follow-up. Recurrence was defined as local (in or adja-
cent to the primary scar), satellite or in-transit (within or
>2 cm of the primary melanoma and the first echelon
nodal basin, respectively), regional (regional nodal basin),
or distant (visceral or distant nodal basin). For all end-
points, patients not experiencing the events were censored
at their date of last follow-up. The term median follow-up
was defined as the median of follow-up time for all
patients calculated from the date of SLNB until death or
last known follow-up date.
The product-limit method of Kaplan andMeier was
used to estimate the survival probabilities. Cox propor-
tional hazards regression was used to assess the possible
association between patient, tumor, and SLNB character-
istics and the time to event endpoints. Because death was
a component for endpoints, age of the patient at biopsy
was expected to be significantly associated. Hence, the
associations of the other characteristics were adjusted for
the patient’s age. Best multivariate models were con-
structed by first modeling all covariates simultaneously,
and then iteratively removing only the most nonsignifi-
cantly associated covariate, re-estimating the mode, and
repeating, until only significant covariates remained.
Patient age, year SLNB was performed (as categorized in
Table 1), histologic features of the primary tumor includ-
ing Breslow depth, mitotic rate (mitosis/mm2), presence
or absence of regression and ulceration, and SLNB status
were included in the multivariate analysis. P values <.05
were considered significant for all statistical tests.
RESULTS
Three hundred fifty-three patients with cutaneous mela-
noma of the head and neck underwent SLNB at the
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University of Michigan between 1997 and 2007. The
median patient age was 53 years (range, 1-87 years). The
median follow-up time was 35 months (range, 3 months
to 10.6 years). The mean Breslow depth was 2.5 mm
(range, 0.6-15.0mm). Ulceration was present in 17.5% of
patients. Detailed patient and tumor data are found in
Table 1. The majority of lesions were located on the scalp
(108 patients, 31%) followed by the face (101 patients,
29%) and neck (76 patients, 22%). A complete list of
head and neck sites involved by melanoma in our data set
is found in Table 2.
At least 1 SLN was identified in 352 patients (99.7%).
There were no patients who sustained permanent cranial
nerve injuries during the SLNB procedure. A small unmeas-
ured subset experienced neuropraxia of a facial nerve branch
that promptly resolved postoperatively. Of the 353 patients,
69 (19.6%) had at least 1 positive SLN. Patients with a posi-
tive SLN had thicker primary tumors (P ¼ .0116) and were
more likely to have ulceration of the primary lesion (P ¼
.0132) (Table 1). Sixty-eight of 69 patients with a positive
SLNB underwent completion lymphadenectomy. Seventeen
patients (25%) in the completion lymphadenectomy group
had at least 1 positive non-SLN.
Of the 283 patients with a negative SLNB, 44
(15.5%) had disease recurrence (Table 3). Overall, there
were 19 regional recurrences, 7 of which were in conjunc-
tion with simultaneous local, in-transit, or distant recur-
rences. Of the 12 patients who recurred first in the
regional basin alone, 9 recurred in the same basin from
which the SLN was originally taken, whereas 3 recurred in
a basin that was not identified as a primary draining basin
during the original SLNB procedure. There were thus 12
false-negative SLNB results. The false-negative rate
(FNR) of our data set was 14.8% (12 false negatives/12
false negatives þ 69 true positives). The negative predic-
tive value of a negative SLNB was 95.8%. Alternatively
Table 1. Patient and Tumor Characteristics by Positivity of
Sentinel Lymph Nodes
Characteristic PSLN Pa
Yes No
Age at SLNB
Mean [SD] 50.2 [21.6] 54.3 [18.4] .1479
Minimum-maximum 6-86 1-87
Age quartiles, No. (%)
1st: £44 years 23 (25.6) 67 (74.4) .0724
2nd: 45-58 years 10 (11.4) 78 (88.6)
3rd: 59-69 years 21 (23.6) 68 (76.4)
4th: 701 years 15 (17.4) 71 (82.6)
Body site, No. (%)
Posterior scalp 8 (25.8) 23 (74.2) .0831
Anterior scalp 15 (35.7 ) 27 (64.3)
Parietal/postauricular 6 (17.1) 29 (82.9)
Forehead/temple/eyebrow 6 (15.8) 32 (84.2)
Preauricular/cheek 9 (16.1) 47 (83.9)
Nose 0 9 (100)
Lip/chin/jawline/submentum 3 (14.3) 18 (85.7)
Anterior/supraclavicular neck 2 (5.7) 33 (94.3)
SCM/posterior neck 5 (25.0) 15 (75.0)
Eye 1 (14.3) 6 (85.7)
Ear 14 (23.7) 45 (76.3)
Year of SLNB
1997-1999 12 (14.5) 71 (85.5) .3087
2000-2004 32 (22.9) 108 (77.1)
2005-2007 25 (19.2) 105 (80.8)
Breslow depth, mm
Mean [SD] 3.0 [1.8] 2.4 [1.8] .0116
Minimum-maximum 0.8-9.0 0.6-15.0
Mitotic rate, per hpf
Mean [SD] 4.4 (5.0) 3.6 (6.3) .2599
Minimum-maximum 0-22.0 0-50.0
Regression
Present 4 (21.1) 15 (78.9) .8629b
Absent 62 (19.4) 257 (80.6)
Unknown 3 (20.0) 12 (80.0)
Ulceration
Present 19 (30.7) 43 (69.3) .0132b
Absent 46 (16.9) 227 (83.1)
Unknown 4 (22.2) 14 (77.8)
Abbreviations: hpf, high-power field; PSLN, positive sentinel lymph node;
SCM, scalene muscle; SD, standard deviation; SLNB, sentinel lymph node
biopsy.
a Chi-square test for categorical covariates and the t test for continuous
covariates.
bUnknown category was omitted from statistical test.
Table 2. Head and Neck Melanoma Sites
Body Site Patients,
No. (%)
Scalp 108 (30.6)
Face 101 (28.6)
Nose 9 (2.5)
Neck 76 (21.5)
Ear 59 (16.7)
Table 3. Site of First Recurrence in Sentinel Lymph
Node-Negative Patients
Site Patients,
No. (%)
Local/in-transit/satellite 7 (15.9)
Regional 12 (27.3)
Distant 14 (31.8)
Local þ regional 4 (9.1)
Local þ distant 4 (9.1)
Local þ regional þ distant 3 (6.8)
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stated, patients with local control and a negative SLNB
failed regionally in 4.2% of cases, which is the false-omis-
sion rate (12 false negatives/12 false negatives þ 271 true
negatives).
Positive SLNB status was the factor most strongly
associated with decreased RFS and decreased OS on univari-
ate analysis (Table 4). The Kaplan-Meier curves for SLNB
status and RFS and OS are presented in Figures 1 and 2,
respectively. A life table for SLNB status and OS is presented
in Table 5. Independent comparison of patients with a posi-
tive non-SLN on completion lymphadenectomy with those
with a negative completion lymphadenectomy did not dem-
onstrate statistically different OS or RFS (Figs. 3, 4).
On multivariate analysis (Tables 6 and 7), positive
SLNB status was the single strongest prognostic factor for
decreased RFS (hazard ratio, 4.23) and decreased OS (haz-
ard ratio, 3.33). Breslow depth of the primary tumor signifi-
cantly decreased RFS (hazard ratio, 1.15), and the presence
of ulceration significantly decreased OS (hazard ratio, 2.05).
DISCUSSION
Our series represents the largest single-institution series of
SLNB for head and neck melanoma to date. Despite con-
cerns about the procedure for this population compared
with truncal or extremity melanomas, SLNB is accurate,
and its results are of prognostic importance for head and
neck melanoma patients. Several important discussion
points, questions, and conclusions result from examina-
tion and interpretation of our data.
In only 1 of 353 consecutive SLNB procedures was
an SLN not identified. This SLNB identification rate of
99.7% and other very high rates in the literature (Table 8)
support the concept that this procedure is feasible in the
head and neck region despite ambiguous lymphatic drain-
age and small lymph node size.5 Our 99.7% SLNB identi-
fication rate in the head and neck region compares
favorably to the nonhead and neck SLNB identification
rate in the Multicenter Selective Lymphadenectomy Trial
1 (97.5%),5 the overall rate in the Sunbelt Melanoma
Trial (99.7%),16 and the European Organization of
Research and Treatment of Cancer data set (100%).17
Previous reports, however, have suggested inferior
SLNB accuracy in the head and neck region relative to
nonhead and neck sites by reporting lower SLNB
Table 4. Univariate Associationsa of the Patient/Tumor
Characteristics and Sentinel Node-Positive Status With
Recurrence-Free Survival
Characteristic P
Breslow depth .0002
Mitotic rate .0372
Regression .6354
Ulceration .0002
PSLNB <.0001
Abbreviation: PSLNB, positive sentinel lymph node biopsy.
a Each association is adjusted for patient age at surgery.
Figure 1. Recurrence-free survival estimates by sentinel
lymph node biopsy status with 95% confidence limits are
shown. PSLN, positive sentinel lymph node.
Figure 2. Overall survival estimates by sentinel lymph node
biopsy status with 95% confidence limits are shown. PSLN,
positive sentinel lymph node.
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positivity rate for the head and neck. For instance, Chao
et al for the Sunbelt Melanoma Trial showed a 20.7%
positive SLNB rate that varied based on the targeted nodal
basin: 23% and 20% for trunk and extremity, respec-
tively, versus 15% for the head and neck (P < .001).6
Other large series also have reported similar SLNB posi-
tivity rates for head and neck melanomas.7,18 Our review
of the literature specifically addressing head and neck mel-
anoma reveals inconsistent SLNB positivity rates across
mainly smaller series. These series showed a low compiled
positivity rate of 13.4% that might suggest decreased ac-
curacy in the head and neck area (Table 8). One may spec-
ulate that lower SLNB positivity rates in the head and
neck region are related to discordant, ambiguous lym-
phatic channels that decrease the chance of identifying the
true SLN. In contrast to previous findings, however, our
large series confirmed a high SLNB positivity rate of
19.7% in the head and neck region, suggesting acceptable
accuracy in the context of the overall rate of positivity for
nonhead and neck melanomas in the Sunbelt Melanoma
Trial (21.4%),6 as well as other reports.7,18
A superior indicator of SLNB accuracy may be the
failure rate of a negative SLNB in predicting regional con-
trol. Comparing failure rates of SLNB across different se-
ries is problematic, as definitions of false negative are often
inconsistent from series to series. Because a local recurrence
could result in a regional recurrence, we define a false-nega-
tive result as a regional recurrence in the absence of a local
or in-transit recurrence. This is in keeping with other large
series specifically addressing regional recurrence after nega-
tive SLNB results.7,19 Although most series report the
FNR to describe SLNB failure, some calculate it correctly
(false negative/false negative þ true positive), whereas
others do not (false negative/false negativeþ true negative).
Table 5. Life Table for SLN Status
Time
Interval, y
SLN Positive SLN Negative
P SE D N P SE D N
0-2 78.5 5.3 13 69 91.7 1.9 18 283
2-4 57.7 7.2 9 41 83.7 2.8 12 176
4-6 50.6 7.9 2 18 75.3 3.8 8 102
6-8 29.5 13.5 2 8 65.0 5.9 6 51
Abbreviations: D, number that died within the interval; N, number at risk at the beginning of the interval; P, product-limit
estimate of survival until the end of the interval; SE, standard error of the survival estimate; SLN, sentinel lymph node.
Figure 3. Recurrence-free survival estimates by sentinel and
nonsentinel lymph node biopsy status with 95% confidence lim-
its are shown. NSLN, nonsentinel lymph node; PNSLN, positive
nonsentinel lymph node; PSLN, positive sentinel lymph node.
Figure 4. Overall survival estimates by sentinel and nonsenti-
nel lymph node biopsy status with 95% confidence limits are
shown. NSLN, nonsentinel lymph node; PNSLN, positive non-
sentinel lymph node; PSLN, positive sentinel lymph node.
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The latter is more accurately termed the false-omission
rate. We consider the false-omission rate to be more clini-
cally relevant, as it represents the proportion of patients
who recur in the nodal basin after a negative SLNB result,
and we will thus use it as our basis for discussion.
Previous data suggest a higher false-omission rate in
the head and neck region relative to nonhead and neck
regions. After recalculations were made where necessary,
the compiled false-omission rate across head and neck
melanoma series with a minimum 30-month follow-up is
9.3%.8,10,20-25 The literature predicts a lower false-omis-
sion rate when considering nonhead and neck melanomas,
including the European Organization for Research and
Treatment of Cancer Melanoma Group data set
(4.7%),17 John Wayne Cancer Center data set (4.8%),26
Multicenter Selective Lymphadenectomy Trial 1
(3.4%),18 and others.7,19 Contrary to previous head and
neck melanoma results, our false-omission rate of 4.2%
demonstrates comparable and acceptable accuracy with
respect to the procedure’s ability to predict regional con-
trol in the head and neck. Stated differently, our data sug-
gest that only 4.2% of patients will recur in any regional
basin (mapped or unmapped) after a negative SLNB
when local control has been achieved.
Examined together, our SLNB positivity rate and
false-omission rate suggest that the accuracy of SLNB is
equivalent between the head and neck region and other
anatomic sites. We attribute the accuracy within our data
set to surgical familiarity with head and neck anatomy by
surgeons specializing exclusively in the head and neck.
Table 6. Best Multivariate Model for Recurrence-Free Survival
Characteristic Hazard Ratio
(95% CI)
P
Breslow depth, 1-mm increase 1.15 (1.04-1.27) .0049
Age at diagnosis, 1-year increase 1.03 (1.02-1.04) <.0001
PSLNB 4.23 (2.73-6.54) <.0001
Abbreviations: CI, confidence interval; PSLNB, positive sentinel lymph node
biopsy.
Table 7. Best Multivariate Model for Overall Survival
Characteristic Hazard Ratio
(95% CI)
P
Ulceration, present vs absent 2.05 (1.22-3.45) .0069
Age at diagnosis, 1-year increase 1.03 (1.02-1.05) <.0001
PSLNB 3.33 (1.99-5.58) <.0001
Abbreviations: CI, confidence interval; PSLNB, positive sentinel lymph node
biopsy.
Table 8. Published Head and Neck-Specific SLNB Data Sets
Study Follow-up,
mo
Total
Patients
Failed
SLNB
SLNB
Identification
Rate, %
Positive
SLNB, No. of
Patients
Positive
SLNB
Rate, %
Bostick 199732 46 117 7 94.0 14 12.7
Wells 199733 11.6 58 3 94.8 6 10.9
Carlson 200034 15.9 58 1 98.3 10 17.5
Jansen 200035 21.5 30 3 90.0 8 29.6
Wagner 200036 10.7 70 0 100.0 12 17.1
Medina-Franco 200137 15 38 3 92.1 4 11.4
Patel 200228 20 56 4 92.9 4 7.7
Schmalbach 200338 25 80 1 98.9 14 17.7
Chao 2003a,6 15.5 321 43
de Wilt 200422 34 136 3 97.8 14 10.5
Shpitzer 200425 31 30 2 93.3 4 14.3
Carlson 200520 34.7 132 7 94.7 22
MacNeil 200539 22.4 44 3 93.2 7 17.6
Leong 2006a,9 39.6 614 62
Doting 200623 54 36 7
Lin 200640 7 114 3 97.4 14 12.6
Telztrow 200721 47 106 12 88.7 17 18.1
Kilpatrick 200741 16 87 7 92.0 14 17.5
Agnese 200742 38.4 131 12
Gomez-Rivera 200810 34 113 0 100.0 23 20.4
Koskivuo 200943 25 0 100.0 4 16.0
Kelly 200924 39.6 40 13 67.5 6 22.2
Total 2776 100 366
Saltman 20108 37 234 16 93.2 28 12.8
Compiled 94.0 13.2
Abbreviation: SLNB, sentinel lymph node biopsy.
aMulti-institutional series.
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Our accuracy may also be secondary to our collective ex-
pertise in nuclear medicine and histopathology.
This data set also substantiates the prognostic impli-
cations of SLNB in patients with head and neck melanoma.
In general, for all cutaneous melanomas, the prognostic
value of SLNB is well known. The analysis of the American
Joint Committee on Cancer’s melanoma database of
>16,000 patients led to the inclusion of nodal micrometa-
stasis in the classification of melanoma TNM stage.27 In
addition, Morton et al showed SLN status to be the most
significant predictor of survival in multivariate analysis in
the biopsy arm of the prospective randomized Multicenter
Selective Lymphadenectomy Trial 1.18
However, head and neck melanoma series have not
consistently put forth convincing evidence to verify the
prognostic significance of SLNB in this region. Smaller se-
ries, such as those of Doting et al, Patel et al, and Gomez-
Rivera et al, failed to elucidate a correlation between SLN
status and survival on multivariate analysis.10,23,28
Through pooled data from>600 patients, Leong et al for
the Sentinel Lymph Node Working Group established a
correlation between SLN status and RFS on multivariate
analysis (hazard ratio, 2.8), but the data was nonsignifi-
cant with regard to OS.9 Saltman et al had similar findings
in their single-institution series of 234 patients.8 On the
basis of our review of the literature, the Winship Cancer
Institute at Emory University is the only group to have
previously put forth evidence through multivariate analy-
sis that SLN status is correlated with OS in head and neck
melanoma through a smaller series of 132 patients.20
This current data set of 353 patients puts forward
powerful data indicating that SLN status is highly prog-
nostic in the head and neck region. Far more predictive
than Breslow depth or ulceration, SLN status was the sin-
gle most prognostic clinicopathologic factor in our series.
We report a hazard ratio for positive SLN status and
decreased RFS at 4.23 (P< .0001) on multivariate analy-
sis (Table 5). The hazard ratio for positive SLN status and
decreased OS was 3.33 (P< .0001) on multivariate analy-
sis (Table 6). These findings are likely a result of both the
previously documented reliability and accuracy of the
SLNB procedure at our institution and our large series
size capable of detecting such correlations.
A question that remains is whether SLNB is safe when
performed in the head and neck region. Some argue the
intricate cranial nerve anatomy and presence of major blood
vessels make SLNB in the head and neck an unsafe practice
relative to other nodal basins. However, the literature does
little to support this premise. Chao et al report 2 permanent
accessory nerve injuries, but no cases of permanent facial
nerve paresis in >300 head and neck SLNB procedures
included in the Sunbelt Melanoma Trial.6 Other large head
and neck melanoma SLNB series do not comment on pro-
cedure-related morbidity.8,9 Picon et al, Loree et al, and
Ollila et al reviewed a combined 134 parotid mapping cases
with a compiled 6% rate of temporary facial nerve paresis,
but no cases of permanent facial paresis.29-31 PubMed
searches using the keywords ‘‘sentinel,’’ ‘‘melanoma,’’ and
‘‘facial nerve’’ failed to identify a reported case of permanent
facial nerve paresis. A similar search yielded no cases of clini-
cally relevant carotid artery injuries. Our series further sup-
ports the safety of the SLNB procedure in the head and
neck. We experienced no reported permanent facial
nerve injuries, damage to other cranial nerves, or clinic-
ally significant vascular injuries in 353 consecutive cases.
Overall, our findings support that SLNB should be
performed in patients with head and neck melanoma for
the same indications as patients with truncal or extremity
melanoma with comparable feasibility, safety, accuracy,
and prognostic value.
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